Furthermore, preclinical data suggest activity of CDK inhibitors in lung cancer xenograft models, and therefore, CDK4/6 inhibitors are currently under investigation for the treatment of advanced lung cancers (74). The gene discussed is CDK4; the disease is lung carcinoma.